Generic Name: isatuximab-irfc
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.
Sarclisa is a cytolytic (cell-killing) antibody that binds to the CD38 protein on myeloma cells and helps the immune system recognize and attack the cancer. It is approved for use in combination with Pomalyst (pomalidomide) and dexamethasone in adults who have received at least two prior therapies including Revlimid (lenalidomide) and a proteasome inhibitor.
In the ICARIA-MM clinical trial of patients with relapsed or refractory (nonresponsive) multiple myeloma who had received at least two prior therapies, Sarclisa plus Pomalyst and low-dose dexamethasone reduced the risk of disease progression or death by 40%. Sarclisa was first approved in March 2020.
Sarclisa is administered as an intravenous infusion every week for four weeks, then every two weeks until disease progression or unacceptable side effects occur.
Common side effects include infusion reactions, upper respiratory tract infections, pneumonia, and diarrhea. Sarclisa can cause depletion of white blood cells (neutropenia and lymphopenia), red blood cells (anemia) and platelets (thrombocytopenia), which can lead to infections, fatigue and easy bleeding. More serious adverse events may include severe infusion reactions and new malignancies. Sarclisa may cause fetal harm if used during pregnancy.
Last Reviewed: March 3, 2020